BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19010862)

  • 1. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
    Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
    Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
    J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
    Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Nasser V; Loriod B; Camerlo J; Tagett R; Tarpin C; Houvenaeghel G; Nguyen C; Maraninchi D; Jacquemier J; Houlgatte R; Birnbaum D; Viens P
    Cancer Res; 2004 Dec; 64(23):8558-65. PubMed ID: 15574762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
    Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
    Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
    Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
    Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
    Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of inflammatory breast cancer.
    Bertucci F; Finetti P; Birnbaum D; Viens P
    Cancer; 2010 Jun; 116(11 Suppl):2783-93. PubMed ID: 20503410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.
    Van Laere S; Van der Auwera I; Van den Eynden GG; Fox SB; Bianchi F; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Breast Cancer Res Treat; 2005 Oct; 93(3):237-46. PubMed ID: 16172796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.
    Nguyen DM; Sam K; Tsimelzon A; Li X; Wong H; Mohsin S; Clark GM; Hilsenbeck SG; Elledge RM; Allred DC; O'Connell P; Chang JC
    Clin Cancer Res; 2006 Sep; 12(17):5047-54. PubMed ID: 16951220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
    Straver ME; Glas AM; Hannemann J; Wesseling J; van de Vijver MJ; Rutgers EJ; Vrancken Peeters MJ; van Tinteren H; Van't Veer LJ; Rodenhuis S
    Breast Cancer Res Treat; 2010 Feb; 119(3):551-8. PubMed ID: 19214742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
    Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
    Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of body mass index in locally advanced breast cancer.
    Dawood S; Broglio K; Gonzalez-Angulo AM; Kau SW; Islam R; Hortobagyi GN; Cristofanilli M
    Clin Cancer Res; 2008 Mar; 14(6):1718-25. PubMed ID: 18347172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis.
    Van Laere S; Van der Auwera I; Van den Eynden G; Van Hummelen P; van Dam P; Van Marck E; Vermeulen PB; Dirix L
    Br J Cancer; 2007 Oct; 97(8):1165-74. PubMed ID: 17848951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.
    Györffy B; Schäfer R
    Breast Cancer Res Treat; 2009 Dec; 118(3):433-41. PubMed ID: 19052860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
    Foekens JA; Atkins D; Zhang Y; Sweep FC; Harbeck N; Paradiso A; Cufer T; Sieuwerts AM; Talantov D; Span PN; Tjan-Heijnen VC; Zito AF; Specht K; Hoefler H; Golouh R; Schittulli F; Schmitt M; Beex LV; Klijn JG; Wang Y
    J Clin Oncol; 2006 Apr; 24(11):1665-71. PubMed ID: 16505412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.